Skip to main
IMVT

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant is a promising company with a potential first-in-class FcRn inhibitor in Difficult-to-Treat RA. The company has a strong pipeline with multiple upcoming catalysts, including potential registrational trial data for IMVT-1402 in GD and MG. The company's current financial situation is solid with sufficient funding to support ongoing operations and potential commercial launch of IMVT-1402. Risks to achieving the price target include regulatory and clinical, COVID-19 impact, and competition in the market.

Bears say

Immunovant is facing potential risks in their upcoming Phase 2 study, as the high efficacy in Period 1 may make Period 2 statistically riskier, potentially hindering their chances of gaining FDA approval. Additionally, the ongoing period 2 study, combined with one more pivotal trial, may not be sufficient for registration, risking delays in bringing their potential treatment to market. With a lack of other significant sources of revenue, the success of their lead product is crucial to the company's financial stability and future growth.

Immunovant Inc (IMVT) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 8 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.